Author

Robin Guild

Observed name: R. Guild

Institution: ImmunoGen (United States)

Observed institutions: Baystate Medical Center, Massachusetts General Hospital, ImmunoGen (United States), The Ohio State University

OpenAlex ID: A5005023596

Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM).

2011 · J. G. Berdeja, S. Ailawadhi, et al. · Journal of Clinical Oncology · 35

Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

2012 · Jesus G. Berdeja, Francisco Hernandez-Ilizaliturri, et al. · Blood · 28

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

2009 · Asher Chanan-Khan, Jeffrey Wolf, et al. · Blood · 23

Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma

2007 · J. McCann, F. V. Fossella, et al. · Journal of Clinical Oncology · 21

Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors.

2011 · P. J. Woll, K. N. Moore, et al. · Journal of Clinical Oncology · 18

Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma

2008 · Asher Alban Chanan-Khan, Mecide Gharibo, et al. · Blood · 8

Phase I/II Study to Assess the Safety, Pharmacokinetics (PK) and Efficacy of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Carboplatin/Etoposide in Patients with Solid Tumors Including Small-Cell Lung Cancer (SCLC)

2012 · D.R. Spigel, J. Bendell, et al. · Annals of Oncology · 4

Works count: 7

Citation count: 137

H-index: 6

I10-index: 5